In recent years, a small non-profit research organization in Boston, Massachusetts, has quietly acquired a significant amount of influence over pricing negotiations in the gargantuan US market for prescription pharmaceuticals.
Founded in the mid-2000s by Steven Pearson, a physician and bioethicist, the Institute for Clinical and Economic Review (ICER) seeks to assess the cost-effectiveness of new health technologies, issuing comprehensive reports that take into account concepts such as value thresholds and the quality-adjusted life year (QALY).
Researched and prepared with participation from industry experts and with the active involvement of stakeholders attending public meetings, these reports frequently determine that a drugmaker’s recommended retail price renders the therapy non-cost effective, providing helpful guidelines on how much of a discount needs to be provided.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze